Stoneham SM, et al38
|
Mar 20-Apr 9, 2020 (20 days)
|
Case-control study
|
21/274 (8%)
|
VTE-positive 67 ± 12 years
VTE-negative 65 ± 15 years
|
VTE-positive:
Men 67%
VTE-negative:
Men 57%
|
3 patients given weight-based treatment with LMWH
|
Overall all-cause mortality rate 27.7%
|
Zhang L, et al39
|
Jan 29-Feb 29, 2020 (31 days)
|
Retrospective cohort study
|
66/143 (46%)
|
63 ± 14 years
|
Men 52%
Women 48%
|
37.1% patients given DVT prophylaxis; 41.3% patients received LMWH after positive ultrasound studies for DVT
|
10.5% patients were admitted to the ICU. DVT patients > 65 years (66.7% vs 41.6%) and critically ill (65.2% vs 28.6%).
|
Cui S, et al40
|
Jan 30-Mar 22, 2020 (23 days)
|
Cohort study, risk analysis
|
20/81 (25%)
|
59.9 ± 14.1 years
|
Men 46%
Women 54%
|
No preventive anticoagulant was administered
|
All admitted to ICU. 41% patients had chronic medical illness. D-dimer level was a good index for predicting VTE.
|
Klok FA, et al41
|
Mar 7-Apr 5, 2020 (29 days)
|
Prospective cohort study
|
75/184 (39%)
|
64 ± 12 years
|
Men 76%
Women 24%
|
All patients received pharmacological thromboprophylaxis per local hospital
|
VTE patients at higher risk of all-cause death (HR 5.4). Anticoagulation lowers risk HR 0.29; all-cause death (HR 0.79, 95%CI 0.35–1.8).
|
Demelo-Rodríguez P, et al42
|
mid-April 2020
|
Prospective observational study
|
23/156 (15%)
|
68.1 ± 14.5 years
|
Men 65%
Women 35%
|
All patients received standard doses of thromboprophylaxis, except 3 patients with high bleeding risk
|
Asymptomatic patients not in-ICU with COVID- 19
|
Pavoni V, et al43
|
Feb 28-Apr 10, 2020 (11 days)
|
Retrospective, observational study
|
20/40 (50%)
|
61 ± 13 years
|
Men 60%
Women 40%
|
All patients received thromboprophylaxis with low molecular weight heparin
|
DVT) in 6 patients (15%) and TBE 2 patients (5%); 12 patients (30%) had a catheter thrombosis
|
Middeldorp S, et al34
|
Mar 2-Apr 12, 2020 (41 days)
|
In-patient cohort study
|
39/198 (20%)
|
61 years
|
Men 66%
Women 34%
|
Ward patients received thrombosis prophylaxis with nadroparin. ICU received a double dose of nadroparin
|
VTE 47% ICU patients, 3% of wards
|
Lodigiani C, et al27
|
Feb 13-Apr 10, 2020 (26 days)
|
Retrospective study
|
60/388 (21%)
|
66 (55–85) years
|
Men 80%
Women 20%
|
All ICU patients received LMWH; general wards: prophylactic 41%, 21% intermediate-, 23% therapeutic dose.
|
Older patients dying during hospitalization (OR 1.10; 95%CI 1.07–1.13). VTE, 27.6% ICU, 6.6% general ward
|
Llitjos JF, et al28
|
Mar 19-Aprl 11, 2020 (23 days)
|
Retrospective cohort study
|
|
68 (51.5–74.5)
|
Men 77%
Women 23%
|
31% treated with prophylactic dose, 69% with therapeutic dose
|
All ICU patients. 56% with VTE
|
Helms J, et al32
|
Mar 3-Mar 31, 2020 (28 days)
|
Multicenter prospective cohort
|
|
63 [53; 71] years
|
Men 81%
Women 19%
|
70% prophylactic dose, 30% therapeutic dose
|
All ICU patients. PE16.7%. COVID-19 ARDS patients developed had more VTE (11.7 vs. 2.1%)
|
Koleilat I, et al44
|
Mar 1-Apr 10, 2020 (40 days)
|
Single center retrospective case-control study
|
18/26 (69%)
|
DVT positive − 59 years
DVT negative − 64 years
|
Men 52%
Women 48%
|
12/18 with chemical thromboprophylaxis; 2/18 therapeutic anticoagulation developed DVT
|
DVT 10.1% either SARS-CoV-2 negative or untested. More COVID-19 patients with DVT
|
Zerwes S, et al45
|
Apr 18-Apr 30, 2020 (12 days)
|
Prospective single center study
|
64/150 (43%)
|
Mean for all patients 67 years; COVID-19 patients 62 years, non-COVID-19 patients 69 years
|
No information
|
Anticoagulation:
9 prophylactic (6 COVID)
3 sub-therapeutic
5 therapeutic.
|
ICU patients: 20 COVID-19-positive patients compared with 20 non-COVID-19 patients. Elevated Ddimer levels.
|
Thomas W, et al46
|
Days of observation = 8 (range 1–28)
|
Observational study
|
17/63 (27%)
|
Estimated average age 61 years
|
Men 69%
Women 31%
|
Prophylactic dalteparin adjusted for weight and renal function or unfractionated heparin
|
All ICU patients. At censor date: Still in ICU 44%; In ward or discharged 32%; Dead 16%
|
Nahum J, et al47
|
Mid-Mar to early Apr 2020 (21 days)
|
Prospective single center study
|
27/34 (79%)
|
62.2 ± 8.6 years
|
Men 78%
Women 22%
|
All patients received anticoagulant prophylaxis at hospital admission
|
All in ICU. VTE 65% at admission, 79% 48 hrs after
|
Longchamp A, et al48
|
Marc 8-Apr 4, 2020
|
Retrospective review
|
8/25 (32%)
|
68 ± 11 years
|
Men 64%
Women 36%
|
Therapeutic anticoagulation only in patients with VTE
|
Discharged 72%
In hospital ICU 2%
Dead 20%
|
Gervaise A, et al49
|
Mar 14-Apr 6, 2020 (23 days)
|
Retrospective review
|
13/72 (18%)
|
APE 74.4 years ± 15.0
non-APE 59.6 years ± 17.4
|
Men 75%
Women 25%
|
Unknown
|
Discharged 38 (53%)
In hospital 23 (32%)
Dead 11 (15%)
|
Mestre-Gómez B, etal50
|
Mar 30-Apr 12, 2020 (13 days)
|
Retrospective review
|
29/91 (32%)
|
65 years (56–73)
|
Men 72%
Women 28%
|
Most patients diagnosed with PE received LMWH, 79.3%
|
Discharged 82.7%; Still In hospital 13.8%; ICU 6.9%; Dead 3.4%
|
Inciardi RM, et al51
|
Mar 4, 2020-Mar 25, 2020 (21 days)
|
Prospective cohort study
|
15/99 (15%)
|
67 ± 12 years
|
Men 81%)
Women 19%
|
Anticogulation not routinely given to patients in sinus rhythm
|
VTE higher in cardiac patients (23% vs. 6%)
Mortality higher in cardiac patients (36% vs. 15%)
|
Soumagne T, etal52
|
Mar 10-Apr 12, 2020 (33 days)
|
Retrospective review
|
56/375 (15%)
|
With PE: 61.1 ± 9.1years
Without PE: 63.5 ± 10.1 years
|
With PE:
Men 84%
Without PE:
Men 76%
|
All patients given anticoagulation at preventive dose
|
Patients with PE vs. Pts without PE
ICU mortality day 14: 16% vs. 26%) p = 0.13
ICU mortality day 28: 29% vs. 37%) p = 0.27
Extubated day 28: 49% vs. 68% p = 0.25
|